Clinical studies of monoamine receptors in the affective disorders and receptor changes with antidepressant treatment

1. 1. Pre-clinical and clinical studies suggest that the responsiveness of monoamine and cholinergic receptors may be altered in the affective disorders and that antidepressants may modify the sensitivity of these receptors. 2. 2. The growth hormone response to clonidine is reduced in depressed patients compared to controls according to several independent studies, suggesting that post-synaptic α₂-adrenergic receptors may be less responsive in depressed patients. 3. 3. The cortisol response to clonidine is enhanced in depressed patients compared to controls in our study raising the possibility that cortisol hypersecretion in depressed patients may be related to noradrenergic dysfunction. 4. 4. The hypotensive response to clonidine is blunted in patients on chronic antidepressant treatment with either clorgyline or desipramine suggesting that pre-synaptic α₂-adrenergic receptors may subsensitize with chronic antidepressant treatment. 5. 5. The prolactin increase in response to fenfluramine is less in depressed patients compared to controls suggesting decreased functional activity of the serotonergic system in depression. 6. 6. Platelet α₂-adrenergic receptor number as measured by tritiated dihydroergocriptine (³H-DHE) binding is increased in depressed patients compared to controls, while cyclic 3'-5' adenosine monophosphate (cAMP) production in response to prostaglandin e₁ (PGE₁) and norepinephrine (NE) inhibition of PGE₁-stimulated cAMP production are reduced in the platelets of depressed patients. Thus, it is not clear that increased ³h-dhe binding reflects increased functional responsiveness and might in fact be compensatory to decreases in functional responses of α₂-adrenergic receptors.